Raising Health AI at the Intersection of Bio with Vijay Pande, Surya Ganguli, and Bowen Liu
Aug 13, 2024
Vijay Pande, a general partner at a16z Bio + Health, is joined by venture partner Surya Ganguli and investing partner Bowen Liu. They dive into how AI is revolutionizing drug development, highlighting its role in identifying new targets and optimizing clinical trials. Discussions touch on the power of large datasets in advancing personalized medicine, as well as the exciting potential of using AI to merge various biological data types. Their perspectives present a captivating look at the future of health technology and research.
AI Snips
Chapters
Transcript
Episode notes
3D Structure Guides Drug Design
- Knowing a protein's 3D structure is key to designing molecules that bind effectively and safely.
- Drug design is multi-objective, requiring AI to balance binding affinity, toxicity, solubility, and synthesis.
AI Tackles Drug Development Inefficiency
- Drug discovery is extremely costly and inefficient, with $2.5B per drug and 90% failure rates.
- Only 800 of 20,000 genes are drug targets, highlighting vast unexplored biology and AI opportunity.
Generative AI for Molecule Design
- Generative AI tackles the inverse design problem by creating molecules with specified properties using diffusion and classifier-guided models.
- Future medicines likely will be novel compounds beyond current commercial libraries, requiring generative creativity.